Shares of Hikma Pharmaceuticals PLC HIK inched down 0.93% to £18.09 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising ...

Shares of Hikma Pharmaceuticals PLC HIK rallied 1.64% to £18.01 Thursday, on what proved to be an all-around poor trading ...

Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Hikma Pharmaceuticals (GB:HIK) has released an update. Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday said it is on track to deliver "another strong performance" following trading to date, and reiterates its full-year revenue expectations.

Companies like Aprecia Pharmaceuticals Co, Austedo, Hikma Pharmaceuticals, and Eagle Pharmaceutical, Inc. are emerging as key players in the Hybrid Medicine market, each leveraging their unique ...

Hikma Pharmaceuticals reiterated its full-year outlook on Thursday on the back of strong trading across the business.

Opioid Withdrawal Treatment market Rising Trends, Demand and Future Scope 2025 to 2034 ...